Co-expression of p53 and bcl-2 proteins in human papillomavirus-induced premalignant lesions of the uterine cervix: Correlation with progression to malignancy

Tumor Biology

Volumn 30, Issue 5-6, 2009, Pages 276-285

  Singh, Madhulika ^a   Srivastava, Smita ^a   Singh, Uma ^b   Mathur, Neeraj ^a   Shukla, Yogeshwer ^a  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Bcl 2; Cervical cancer; Human papillomavirus; P53; Squamous intraepithelial lesion

Indexed keywords

BIOTIN; PEROXIDASE; PROTEIN BCL 2; PROTEIN P53; REGULATOR PROTEIN; STREPTAVIDIN; VIRUS DNA;

ADULT; APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DNA DETERMINATION; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; INFECTION RISK; MAJOR CLINICAL STUDY; PRECANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SQUAMOUS CELL; SQUAMOUS EPITHELIUM; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; VIRUS CARCINOGENESIS; VIRUS DETECTION; VIRUS IDENTIFICATION; VIRUS INFECTION; WART VIRUS;

EID: 70450173171     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1159/000259911     Document Type: Article

References (48)

1. Meijer CJ, Van den Brule AJ, Snijders PJ, Helmerhorst T, Kenemans P, Walboomers JM: Detection of human papillomavirus in cervical scrapes by the polymerase chain reaction in relation to cytology: possible implications for cervical cancer screening. IARC Sci Publ 1992; 119: 271-281.
2. Jay N, Moscicki AB: Human papillomavirus infections in women with HIV disease: prevalence, risk, and management. AIDS Read 2000; 10: 659-668.
3. Murakami M, Gurski KJ, Steller MA: Human papillomavirus vaccines for cervical cancer. J Immunother 1999; 22: 212-218.
4. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423-428.
5. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
6. Hudelist G, Manavi M, Pischinger KI, Watkins-Riedel T, Singer CF, Kubista E, Czerwenka KF: Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol 2004; 92: 873-880.
7. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J: Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 2005; 99(suppl):S7-S11.
8. Nair P, Nair MK, Jayaprakash PG, Pillai MR: Decreased programmed cell death in the uterine cervix associated with high risk human papillomavirus infection. Pathol Oncol Res 1999; 5: 95-103.
9. Helland A, Holm R, Kristensen G, Kaern J, Karlsen F, Trope C, Nesland JM, Borresen AL: Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas. J Pathol 1993; 171: 105-114.
10. Grace VM, Shalini JV, Iekha TT, Devaraj SN, Devaraj H: Co-overexpression of p53 and Bcl-2 proteins in HPV-induced squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2003; 91: 51-58.
11. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 1991; 351: 453-456.
12. Hockenbery DM: The Bcl-2 oncogene and apoptosis. Semin Immunol 1992; 4: 413-420.
13. Pan H, Yin C, Van Dyke T: Apoptosis and cancer mechanisms. Cancer Surveys 1997; 29: 305-327.
14. Waga S, Hannon GJ, Beach D, Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574-578.
15. Takahashi R: Role of p53 tumor suppressor gene and Fas/Apo-1 in induction of apoptosis and differentiation of cancer cells. Leukemia 1997; 11: 331-333.
16. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM: Down regulation of Bcl-2 by p53 in breast cancer cells. Cancer Res 1994; 54: 2095-2097.
17. Henriksen R, Wilander E, Oberg K: Expression and prognostic significance of Bcl-2 in ovarian tumours. Br J Cancer 1995; 72: 1324-1329.
18. Nguyen PL, Zukerberg LR, Benedict WF, Harris NL: Immunohistochemical detection of p53, Bcl-2 and retinoblastoma proteins in follicular lymphoma. Am J Clin Pathol 1996; 105: 538-543.
19. Popescu RA, Lohri A, De Kant E, Thiede C, Reuter J, Hermann R, Rochlitz CF: Bcl-2 expression is reciprocal to p53 and c-myc expression in metastatic human colorectal cancer. Eur J Cancer 1998; 34: 1268-1273.
20. Tjalma WA, Weyler JJ, Bogers JJ, Pollefliet C, Baay M, Goovaerts GC, Vermorken JB, Van Dam PA, Van Marck EA, Buytaert PM: The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol 2001; 97: 223-230.
21. Clarke B, Chetty R: Cell cycle aberrations in the pathogenesis of squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2001; 82: 238-246.
22. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC: Tumour suppressor p53 is a regulator of Bcl-2 and base gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-1805.
23. Yang E, Korsmeyer SJ: Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. Blood 1996; 88: 386-401.
24. Snijders PJ, Van den Brule AJ, Schrijnemakers HF, Snow G, Meijer CJ, Walboomers JM: The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol 1990; 71: 173-181.
25. Van den Brule AJ, Snijders PJ, Raaphorst PM, Schrijnemakers HF, Delius H, Gissmann L, Meijer CJ, Walboomers JM: General primer polymerase chain reaction in combination with sequence analysis for identification of potentially novel human papillomavirus genotypes in cervical lesions. J Clin Microbiol 1992; 30: 1716-1721.
26. Bauer HM, Manos MM: PCR detection of genital human papillomavirus; in Persing D, Smith TF, Tenover FC, White TJ (eds): Diagnostic Molecular Microbiology. Washington, ASM Press, 1993, pp 407-413.
27. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M: Elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-1079.
28. McCluggage WG: Immunohistochemical and functional biomarkers of value in female genital tract lesions. Int J Gynecol Pathol 2006; 25: 101-120.
29. Baalbergen A, Ewing-Graham PC, Eijkemans MJ, Helmerhors TJM: Prognosis of adenocarcinoma of the uterine cervix: p53 expression correlates with higher incidence of mortality. Int J Cancer 2007; 121: 106-110.
30. Oka K, Nakano T, Arai T: p53 CM-1 expression is not associated with prognosis in uterine cervical carcinoma. Cancer 1993; 72: 160-164.
31. Tsuda H, Hirohashi S: Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes. Jpn J Cancer Res 1992; 83: 1184-1191.
32. Dimitrakakis C, Kymionis G, Diakomanolis E, Papaspyrou I, Rodolakis A, Arzimanoglou I, Leandros E, Michalas S: The possible role of p53 and Bcl-2 expression in cervical carcinomas and their premalignant lesions. Gynecol Oncol 2000; 77: 129-136.
33. Shi J, Zheng JS, Yin F, Hu WW, Huang XJ, Zhou XL: Association of p16, p53, Ki-67 expressions with high-risk human papilloma virus infection in cervical intraepithelial neoplasia (in Chinese). Nan Fang Yi Ke Da Xue Xue Bao 2007; 27: 515-517.
34. Vassallo J, Derchain SFM, Pinto GA, Martinez EZ, Syranen KJ, Andrade LAL: High risk HPV and p53 protein expression in cervical intraepithelial neoplasia. Int J Gynecol Obstet 2000; 71: 45-48.
35. O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG: An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol 2005; 29: 1034-1041.
36. Ikuta A, Saito J, Mizokami T, Nakamoto T, Yasuhara M, Nagata F, Nakajima M, Matsuo I, Yasuda K, Kanzaki H: Correlation p53 expression and human papilloma virus deoxyribonucleic acid with clinical outcome in early uterine cervical carcinoma. Cancer Detect Prev 2005; 29: 528-536.
37. Thomas M, Pim D, Banks L: The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 1999; 15: 7690-7700.
38. Crook T, Fisher C, Masterson PJ, Vousden KH: Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene 1994; 9: 1225-1230.
39. Liang XH, Mungal S, Ayscue A, Meissner JD, Wodnicki P, Hockenbery D, Lockett S, Herman B: Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. J Cell Biochem 1995; 57: 509-521.
40. Saitoh Y, Yaginuma Y, Ishikawa M: Analysis of Bcl-2, Bax and Survivin genes in uterine cancer. Int J Oncol 1999; 15: 137-141.
41. Aletra C, Ravazoula P, Scopa C, Kounelis S, Sotiropoulou G, Kourounis G, Ladopoulos I, Bonikos D: Expression of bcl-2 and bax in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the uterine cervix. Eur J Gynaecol Oncol 2000; 21: 494-498.
42. Fonseca-Moutinho JA, Cruz E, Carvalho L, Prazeres HJM, De Lacerda MMP, da Silva DP, Mota F, De Oliveira CF: Estrogen receptor, progesterone receptor, and bcl-2 are markers with prognostic significance in CIN III. Int J Gynecol Cancer 2004; 14: 911-920.
43. Pillai MR, Halabi S, McKalip A, Jayaprakash PG, Rajalekshmi TN, Nair MK, Herman B: The presence of human papillomavirus-16/ -18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer. Cancer Epidemiol Biomarkers Prev 1996; 5: 329-335.
44. Saegusa M, Takano Y, Hashimura M, Shoji Y, Okayasu I: The possible role of Bcl-2 expression in the progression of tumors of the uterine cervix. Cancer 1995; 76: 2297-2303.
45. Oltvai ZN, Korsmeyer SJ: Checkpoints of dueling dimers foil death wishes. Cell 1994; 79: 189-192.
46. Sidransky D, Hollstein M: Clinical implications of the p53 gene. Annu Rev Med 1996; 47: 285-301.
47. Wootipoom V, Lekhyananda N, Phungrassami T, Boonyaphiphat P, Thongsuksai P: Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy. Gynecol Oncol 2004; 94: 636-642.
48. Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, Ferenczy A, Rohan TE, Villa LL, Franco EL: Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003; 95: 1336-1343. (Pubitemid 37160867)